THOMAS PEARCE: Open Payments
NPI 1053306589 · GLOUCESTER, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,107 in 46 payments from 18 companies in 2025. Trend: 2023 $2,909 · 2024 $2,011 · 2025 $1,107
Food & beverage: $1,107
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $147 |
| Novo Nordisk Inc | 2 | $125 |
| Novartis Pharmaceuticals Corporation | 4 | $108 |
| Aimmune Therapeutics, Inc. | 5 | $103 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $99 |
| AstraZeneca Pharmaceuticals LP | 4 | $78 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $75 |
| Amgen Inc. | 3 | $69 |
| PFIZER INC. | 3 | $67 |
| Teva Pharmaceuticals USA, Inc. | 2 | $54 |
Products named: Ozempic, LEQVIO, ZENPEP, TRINTELLIX, Kerendia, UBRELVY, PREVNAR 20, AUSTEDO XR.
Industry payments across MA — which companies pay providers there.
